Proficio Capital Partners LLC Acquires Shares of 30,717 Twist Bioscience Co. (NASDAQ:TWST)

Proficio Capital Partners LLC bought a new stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 30,717 shares of the company's stock, valued at approximately $1,427,000. Proficio Capital Partners LLC owned 0.05% of Twist Bioscience as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in TWST. State Street Corp raised its holdings in shares of Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company's stock valued at $143,101,000 after buying an additional 526,028 shares during the period. Wellington Management Group LLP increased its stake in Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company's stock worth $36,042,000 after purchasing an additional 521,272 shares during the period. Jennison Associates LLC boosted its stake in shares of Twist Bioscience by 80.2% in the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock valued at $31,636,000 after purchasing an additional 302,884 shares during the period. ARK Investment Management LLC grew its holdings in shares of Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after purchasing an additional 237,772 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Twist Bioscience by 81.9% during the 4th quarter. Principal Financial Group Inc. now owns 374,551 shares of the company's stock worth $17,405,000 after buying an additional 168,687 shares during the period.

Remove Ads

Twist Bioscience Stock Up 4.8 %

Twist Bioscience stock traded up $2.05 during mid-day trading on Monday, hitting $44.94. The company had a trading volume of 725,329 shares, compared to its average volume of 924,609. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The business has a fifty day moving average of $45.40 and a 200 day moving average of $45.27. The stock has a market cap of $2.68 billion, a price-to-earnings ratio of -13.30 and a beta of 2.15.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same period last year, the firm posted ($0.75) EPS. The company's revenue was up 24.1% on a year-over-year basis. On average, sell-side analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on TWST shares. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the company an "overweight" rating in a research report on Monday, February 3rd. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. TD Cowen restated a "buy" rating and set a $58.00 price target on shares of Twist Bioscience in a report on Tuesday, November 26th. JPMorgan Chase & Co. lifted their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an "underweight" rating in a research note on Tuesday, February 4th. Finally, Robert W. Baird upped their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $54.40.

Insider Transactions at Twist Bioscience

In other news, SVP Paula Green sold 918 shares of the firm's stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. This trade represents a 0.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emily M. Leproust sold 1,726 shares of the company's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the completion of the sale, the chief executive officer now owns 660,966 shares of the company's stock, valued at approximately $27,549,062.88. This trade represents a 0.26 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,799 shares of company stock worth $1,593,944. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.